Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

Media Contacts:
Kristy Marks
Director, Corporate Communications, Bausch + Lomb

Teresa Panas
BioComm Network, Inc., on behalf of Bausch + Lomb

Preloaded Single-use Injector Simplifies CTR Implantation

BRIDGEWATER, New Jersey, July 12, 2017 – Bausch + Lomb, a leading global eye health company, today announced the U.S. launch of the FortifEYE™ capsular tension ring (CTR).

“Capsular tension rings can play an important role in complex cataract cases, and they must be both effective and easy to use during these procedures,” said Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb. “The FortifEYE CTR with preloaded single-use injector simplifies insertion allowing for safe, immediate preparation and use.”1

The FortifEYE CTR is a pre-loaded, sterile, non-optical implant2 indicated for the stabilization of the crystalline lens capsule in the presence of weak or partially absent zonules in adult patients undergoing cataract extraction with intraocular lens implantation. Conditions associated with weak or partially absent zonules may include primary zonular weakness (e.g., Marfan syndrome), secondary zonular weakness (e.g., trauma or vitrectomy), cases of zonulysis, cases of pseudoexfoliation, and cases of Weill-Marchesani syndrome.3

The FortifEYE CTRs are sterile, non-optical implants made up of one continuous piece of polymethyl methacrylate (PMMA), available in both clockwise (right-handed) and counterclockwise (left-handed) insertion options, and are available in a variety of diameters, including 10mm, 11mm, and 12mm (compressed).4

CTRs have been shown to preserve the integrity of the capsular bag diameter, capsulorhexis size, and IOL shape, allowing for good anatomical IOL centration.5* CTRs also have been shown to be a safe and effective ancillary method to delay the incidence, onset, and magnitude of posterior capsular opacification6,7,8 and reduce postsurgical decentration and tilt to allow for excellent optical performance of multifocal and plate-haptic IOLs.9,10,11

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people’s eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries.


*Results from an in vitro study

FortifEYE is a trademark of Bausch & Lomb Incorporated or its affiliates.
© 2017 Bausch & Lomb Incorporated. FEY.0018.USA.17

1 FortifEYE [instructions for use]. Rochester, NY: Bausch & Lomb Incorporated; 2017.

2 FortifEYE [instructions for use]. Rochester, NY: Bausch & Lomb Incorporated; 2017.

3 FortifEYE [instructions for use]. Rochester, NY: Bausch & Lomb Incorporated; 2017.

4 FortifEYE [instructions for use]. Rochester, NY: Bausch & Lomb Incorporated; 2017.

5 Lee DH, Lee HW, Lee KH, Chung KH, Joo CK. Effect of a capsular tension ring on the shape of the capsular bag and opening and the intraocular lens. J Cataract Refract Surg. 2001;27(3):452-456.

6 Kim JH, Kim H, Joo CK. The effect of capsular tension ring on posterior capsular opacity in cataract surgery. Korean J Ophthalmol. 2005;19(1):23-28.

7 D’Eliseo D, Pastena B, Longanesi L, Grisanti F, Negrini V. Prevention of posterior capsule opacification using capsular tension ring for zonular defects in cataract surgery. Eur J Ophthalmol. 2003;13(2):151-154.

8 Summary of safety and effectiveness data. FDA January 2002, PMA P010059.

9 Alió JL, Elkady B, Ortiz D, Bernabeu G. Microincision multifocal intraocular lens with and without a capsular tension ring: optical quality and clinical outcomes. J Cataract Refract Surg. 2008;34(9):1468-1475.

10 Price FW Jr, Mackool RJ, Miller KM, Koch P, Oetting TA, Johnson AT. Interim results of the United States investigational device study of the Ophtec capsular tension ring. Ophthalmology. 2005;112(3):460-465.

11 Takimoto M, Hayashi K, Hayashi H. Effect of a capsular tension ring on prevention of intraocular lens decentration and tilt and on anterior capsule contraction after cataract surgery. Jpn J Ophthalmol. 2008;52(5):363-367. 

Actions: E-mail | Permalink |